Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

Immunity

Volumn 44, Issue 2, 2016, Pages 343-354

  Pfirschke, Christina ^a   Engblom, Camilla ^a,b   Rickelt, Steffen ^c   Cortez Retamozo, Virna ^a   Garris, Christopher ^a,b   Pucci, Ferdinando ^a   Yamazaki, Takahiro ^d   Poirier Colame, Vichnou ^d   Newton, Andita ^a   Redouane, Younes ^a   Lin, Yi Jang ^a   Wojtkiewicz, Gregory ^a   Iwamoto, Yoshiko ^a   Mino Kenudson, Mari ^a   Huynh, Tiffany G ^a   Hynes, Richard O ^c   Freeman, Gordon J ^b   Kroemer, Guido ^d   Zitvogel, Laurence ^d   Weissleder, Ralph ^a   Pittet, Mikael J ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CASPASE 3; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DOCETAXEL; DOXORUBICIN; HIGH MOBILITY GROUP B1 PROTEIN; MAFOSFAMIDE; MITOXANTRONE; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; PLATINUM COMPLEX; TLR4 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; FIBROSARCOMA; GENETIC MODEL; HUMAN; HUMAN TISSUE; IMMUNOGENIC CHEMOTHERAPY; IMMUNOGENICITY; INNATE IMMUNITY; LUNG ADENOCARCINOMA; LYMPHOCYTIC INFILTRATION; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MOUSE MODEL; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE K RAS; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; SENSITIZATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CENTRAL NERVOUS SYSTEM SENSITIZATION; DISEASE MODEL; DRUG EFFECTS; DRUG THERAPY; GENE; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; LUNG NEOPLASMS; METABOLISM; PROCEDURES; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM SENSITIZATION; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; DRUG THERAPY; GENES, CDC; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGANOPLATINUM COMPOUNDS; TOLL-LIKE RECEPTOR 4;

EID: 84958124766     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2015.11.024     Document Type: Article

References (42)

1. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
2. Broz M.L., Krummel M.F. The emerging understanding of myeloid cells as partners and targets in tumor rejection. Cancer Immunol. Res. 2015, 3:313-319.
3. Broz M.L., Binnewies M., Boldajipour B., Nelson A.E., Pollack J.L., Erle D.J., Barczak A., Rosenblum M.D., Daud A., Barber D.L., et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 2014, 26:638-652.
4. Casanova J.L., Abel L., Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu. Rev. Immunol. 2011, 29:447-491.
5. Chauhan V.P., Stylianopoulos T., Martin J.D., Popović Z., Chen O., Kamoun W.S., Bawendi M.G., Fukumura D., Jain R.K. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 2012, 7:383-388.
6. Ciampricotti M., Hau C.S., Doornebal C.W., Jonkers J., de Visser K.E. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat. Med. 2012, 18:344-346. author reply 346.
7. Cortez-Retamozo V., Etzrodt M., Newton A., Rauch P.J., Chudnovskiy A., Berger C., Ryan R.J., Iwamoto Y., Marinelli B., Gorbatov R., et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl. Acad. Sci. USA 2012, 109:2491-2496.
8. Cortez-Retamozo V., Etzrodt M., Newton A., Ryan R., Pucci F., Sio S.W., Kuswanto W., Rauch P.J., Chudnovskiy A., Iwamoto Y., et al. Angiotensin II drives the production of tumor-promoting macrophages. Immunity 2013, 38:296-308.
9. De Palma M., Lewis C.E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013, 23:277-286.
10. DuPage M., Cheung A.F., Mazumdar C., Winslow M.M., Bronson R., Schmidt L.M., Crowley D., Chen J., Jacks T. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011, 19:72-85.
11. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306.
12. Gajewski T.F., Schreiber H., Fu Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013, 14:1014-1022.
13. Gao Q., Qiu S.J., Fan J., Zhou J., Wang X.Y., Xiao Y.S., Xu Y., Li Y.W., Tang Z.Y. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 2007, 25:2586-2593.
14. Ghiringhelli F., Larmonier N., Schmitt E., Parcellier A., Cathelin D., Garrido C., Chauffert B., Solary E., Bonnotte B., Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 2004, 34:336-344.
15. Gou H.F., Huang J., Shi H.S., Chen X.C., Wang Y.S. Chemo-immunotherapy with oxaliplatin and interleukin-inhibits colon cancer metastasis in mice. PLoS ONE 2014, 9:e85789.
16. Gubin M.M., Zhang X., Schuster H., Caron E., Ward J.P., Noguchi T., Ivanova Y., Hundal J., Arthur C.D., Krebber W.J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515:577-581.
17. Herbst R.S., Soria J.C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
18. +/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013, 24:589-602.
19. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 2013, 31:51-72.
20. Lu L., Xu X., Zhang B., Zhang R., Ji H., Wang X. Combined PD-blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J. Transl. Med. 2014, 12:36.
21. Lutsiak M.E., Semnani R.T., De Pascalis R., Kashmiri S.V., Schlom J., Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105:2862-2868.
22. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
23. Oliver T.G., Mercer K.L., Sayles L.C., Burke J.R., Mendus D., Lovejoy K.S., Cheng M.H., Subramanian A., Mu D., Powers S., et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 2010, 24:837-852.
24. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
25. Postow M.A., Chesney J., Pavlick A.C., Robert C., Grossmann K., McDermott D., Linette G.P., Meyer N., Giguere J.K., Agarwala S.S., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015, 372:2006-2017.
26. Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., Lee W., Yuan J., Wong P., Ho T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-blockade in non-small cell lung cancer. Science 2015, 348:124-128.
27. Rooney M.S., Shukla S.A., Wu C.J., Getz G., Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015, 160:48-61.
28. Ruffell B., Chang-Strachan D., Chan V., Rosenbusch A., Ho C.M., Pryer N., Daniel D., Hwang E.S., Rugo H.S., Coussens L.M. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 2014, 26:623-637.
29. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A.A., Frosina D., Gnjatic S., Ambrosone C., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102:18538-18543.
30. Schiavoni G., Sistigu A., Valentini M., Mattei F., Sestili P., Spadaro F., Sanchez M., Lorenzi S., D'Urso M.T., Belardelli F., et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2011, 71:768-778.
31. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
32. Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science 2015, 348:69-74.
33. Shalapour S., Font-Burgada J., Di Caro G., Zhong Z., Sanchez-Lopez E., Dhar D., Willimsky G., Ammirante M., Strasner A., Hansel D.E., et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 2015, 521:94-98.
34. Sharma P., Allison J.P. The future of immune checkpoint therapy. Science 2015, 348:56-61.
35. Spranger S., Bao R., Gajewski T.F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015, 523:231-235.
36. Tesniere A., Schlemmer F., Boige V., Kepp O., Martins I., Ghiringhelli F., Aymeric L., Michaud M., Apetoh L., Barault L., et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010, 29:482-491.
37. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
38. Topalian S.L., Drake C.G., Pardoll D.M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015, 27:450-461.
39. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65:87-108.
40. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J., Robert L., Chmielowski B., Spasic M., Henry G., Ciobanu V., et al. PD-blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571.
41. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133.
42. Zitvogel L., Galluzzi L., Smyth M.J., Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013, 39:74-88.